Literature DB >> 12096147

Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion.

T K Hartung1, E Schofield, A I Short, M J A Parr, J A Henry.   

Abstract

BACKGROUND: Life-threatening and fatal hyponatraemic complications following ecstasy use have previously been documented. AIM: To define clinical features of hyponatraemia following the ingestion of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy').
DESIGN: Retrospective case series.
METHODS: All enquiries to the London centre of the National Poisons Information Service (NPIS) between December 1993 and March 1996 were screened for cases of MDMA use associated with hyponatraemia (serum sodium <130 mmol/l). History of fluid consumption, presenting features and subsequent clinical course were recorded.
RESULTS: Seventeen patients, aged 15-26 years, were identified. Serum sodium levels ranged between 107 mmol/l and 128 mmol/l. In six patients, biochemical results were consistent with inappropriate secretion of antidiuretic hormone (SIADH). Analytical confirmation of MDMA ingestion was obtained in 10 patients. Ten patients were known to have ingested a large amount of non-alcoholic or alcoholic fluid. The clinical pattern was remarkably uniform, with initial vomiting and disturbed behaviour, followed in 11 patients by seizures. Drowsiness, a mute state and disorientation were observed for up to 3 days. Two patients died; 14 made a complete recovery. DISCUSSION: MDMA can cause life-threatening hyponatraemic encephalopathy when accompanied by excessive fluid ingestion. The mechanism involves inappropriate secretion of antidiuretic hormone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096147     DOI: 10.1093/qjmed/95.7.431

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  16 in total

1.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

Review 2.  Arginine vasopressin, fluid balance and exercise: is exercise-associated hyponatraemia a disorder of arginine vasopressin secretion?

Authors:  Tamara Hew-Butler
Journal:  Sports Med       Date:  2010-06-01       Impact factor: 11.136

3.  H2O coma.

Authors:  Dorothea Stiefel; Axel Petzold
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

4.  Diabetic ketoacidosis complicated by the use of ecstasy: a case report.

Authors:  Mirnaluci Paulino Ribeiro Gama; Bárbara Vicente de Souza; Ana Carolina Ossowski; Rafaela Cristina Perraro
Journal:  J Med Case Rep       Date:  2010-08-03

Review 5.  Brain amino acids during hyponatremia in vivo: clinical observations and experimental studies.

Authors:  Lourdes Massieu; Teresa Montiel; Georgina Robles; Octavio Quesada
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

Review 6.  Nephrotoxic effects of designer drugs: synthetic is not better!

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2014-03-25       Impact factor: 28.314

7.  Exercise-associated hyponatraemia after a marathon: case series.

Authors:  A M Goudie; D S Tunstall-Pedoe; M Kerins; J Terris
Journal:  J R Soc Med       Date:  2006-07       Impact factor: 18.000

Review 8.  Psychostimulants and movement disorders.

Authors:  Andres Asser; Pille Taba
Journal:  Front Neurol       Date:  2015-04-20       Impact factor: 4.003

9.  Methylenedioxymethamphetamine (MDMA)-Induced Hyponatremia: Case Report and Literature Review.

Authors:  Sherif Elkattawy; Ahmed Mowafy; Islam Younes; Marina Tucktuck; James Agresti
Journal:  Cureus       Date:  2021-05-25

Review 10.  Clinical review: Major consequences of illicit drug consumption.

Authors:  Robert J Devlin; John A Henry
Journal:  Crit Care       Date:  2008-01-08       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.